Brokerages Set ICON Public Limited (NASDAQ:ICLR) PT at $283.92

ICON Public Limited (NASDAQ:ICLR) has received an average recommendation of “Moderate Buy” from the fifteen research firms that are covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation, eleven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $281.00.

A number of analysts have recently weighed in on ICLR shares. JPMorgan Chase & Co. reduced their price objective on shares of ICON Public from $280.00 to $265.00 and set an “overweight” rating for the company in a research note on Monday, February 3rd. Barclays reduced their price objective on shares of ICON Public from $275.00 to $240.00 and set an “overweight” rating for the company in a research note on Friday. Royal Bank of Canada reiterated an “outperform” rating and set a $263.00 target price on shares of ICON Public in a research note on Wednesday, January 15th. Robert W. Baird cut their target price on shares of ICON Public from $249.00 to $225.00 and set a “neutral” rating for the company in a research note on Wednesday, November 20th. Finally, Leerink Partners reiterated an “outperform” rating and set a $255.00 target price (down from $270.00) on shares of ICON Public in a research note on Tuesday, November 19th.

Institutional Investors Weigh In On ICON Public

Large investors have recently made changes to their positions in the company. Sierra Ocean LLC bought a new stake in ICON Public during the 4th quarter worth about $29,000. Park Place Capital Corp grew its holdings in ICON Public by 281.4% during the 4th quarter. Park Place Capital Corp now owns 225 shares of the medical research company’s stock worth $47,000 after acquiring an additional 166 shares during the last quarter. Private Trust Co. NA grew its holdings in ICON Public by 48.8% during the 4th quarter. Private Trust Co. NA now owns 250 shares of the medical research company’s stock worth $52,000 after acquiring an additional 82 shares during the last quarter. GAMMA Investing LLC grew its holdings in ICON Public by 64.0% during the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock worth $91,000 after acquiring an additional 169 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. grew its holdings in ICON Public by 23.1% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company’s stock worth $147,000 after acquiring an additional 96 shares during the last quarter. Institutional investors own 95.61% of the company’s stock.

ICON Public Price Performance

Shares of ICON Public stock opened at $201.39 on Friday. The firm has a fifty day simple moving average of $202.90 and a 200-day simple moving average of $244.47. The company has a current ratio of 1.26, a quick ratio of 1.34 and a debt-to-equity ratio of 0.36. ICON Public has a 1-year low of $181.51 and a 1-year high of $347.72. The stock has a market capitalization of $16.61 billion, a price-to-earnings ratio of 21.13, a PEG ratio of 1.86 and a beta of 1.19.

ICON Public (NASDAQ:ICLR) last issued its quarterly earnings data on Wednesday, February 19th. The medical research company reported $3.42 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.01. ICON Public had a net margin of 9.56% and a return on equity of 11.81%. The business had revenue of $2.04 billion during the quarter, compared to analysts’ expectations of $2.04 billion. On average, sell-side analysts expect that ICON Public will post 13.38 earnings per share for the current year.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.